We found that, despite not having representatives of their families, TLR7, BCL2, EZH2, and MDM2 for example, scored highly using the druggability models (74% or higher using the all-drug-target model; and 85% or higher using the cancer-drug-target model). The gene discussed is TLR7; the disease is cancer.